Paige partners with Ohio State Wexner Medical Center to assess AI’s role in precise prostate cancer diagnosis in community hospitals. The collaboration employs the FDA-approved Paige Prostate Detect AI tool to gauge diagnostic accuracy, efficiency, and cost-effectiveness. The study involves comparing AI-assisted diagnoses with traditional methods, focusing on real-world data from community pathologists. By analyzing outcomes, time, and resource usage, the research aims to bolster confidence in AI-supported diagnostics for prostate cancer patients. This collaboration reflects the potential of AI in community healthcare settings and its transformative impact on pathology practices.
Paige, a global frontrunner in comprehensive digital pathology solutions and clinical AI applications for cancer diagnosis, has unveiled a strategic partnership with Ohio State University Wexner Medical Center (OSWMC) and its associated community healthcare facilities. Together, they are embarking on a multifaceted investigation into the clinical utility and economic implications of employing AI tools for cancer diagnosis within the context of community hospitals. This collaborative effort will gauge the precision, efficiency, and cost-effectiveness that AI brings to diagnosing cancer in these settings. Utilizing the Paige Prostate Suite, including the esteemed Paige Prostate Detect, the sole AI-powered pathology algorithm with FDA approval for detecting prostate cancer, OSWMC is poised to assess the discernible disparities between diagnoses made with and without the integration of AI technology.
Having already demonstrated its capability to enhance prostate cancer detection, Paige Prostate will now undergo an insightful real-world data retrospective analysis by prominent community hospital pathologists. The aim is to scrutinize the differential accuracy and efficiency with which general surgical pathologists identify, categorize, and quantify prostate cancers, both with and without the support of the Paige Prostate Suite, in comparison to specialist-guided reference diagnoses. Furthermore, this study will delve into variations in time and resource utilization stemming from AI utilization. This qualitative exploration seeks to ascertain the tangible effects of Paige’s AI applications on community pathologists, taking into account aspects such as access to specialist expertise, patient treatment pathways, and confidence levels in diagnoses, whether facilitated by Paige’s AI or not.
Dr. David Klimstra, Co-Founder and Chief Medical Officer at Paige, highlighted, “With the American Cancer Society projecting over 288,000 new prostate cancer cases in the United States in 2023, a significant portion of which could be fatal, the study conducted by OSWMC and its affiliates holds the promise of illuminating the extent to which AI can enhance diagnostic capabilities. This, in turn, can instill confidence among pathologists and oncologists, ensuring the accuracy and efficiency of AI support in the diagnosis and treatment of prostate cancer patients.”
Andrea Parke, Global Director of Clinical Science and Partnerships at Paige, emphasized the substantial advantages that the Paige Prostate Suite, a virtual expert companion in the digital realm, could offer in a community healthcare setting. Parke noted that this pioneering study not only seeks to fathom the impact of Paige Prostate on diagnostic precision in such settings but also endeavors to quantify the temporal and resource-related efficiencies achievable through AI-driven workflows.
OSWMC, having meticulously curated the study cohort, anticipates commencing study assessments later this month. Dr. Swati Satturwar, Clinical Assistant Professor of Pathology and the Principal Investigator of the study hailed AI-fueled diagnostic solutions like Paige as transformative forces poised to revolutionize the field of pathology. Dr. Satturwar expressed that the collaborative retrospective analysis with Paige is poised to showcase the efficacy of AI within the community healthcare landscape, thereby contributing substantial real-world evidence to foster the mainstream integration of AI for routine clinical practices.
